Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MiroBio
The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.
Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.
- Large Molecule